Gilboa Therapeutics
Gilboa Therapeutics is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Gilboa Therapeutics.
Gilboa Therapeutics is a company.
Key people at Gilboa Therapeutics.
Key people at Gilboa Therapeutics.
Gilboa Therapeutics is a preclinical-stage biopharmaceutical company developing SolidT, a novel engineered T cell therapy platform for cancer immunotherapy.[1][2][3] It targets solid and hematological tumors by genetically modifying patient T cells to express a high-affinity antibody receptor that activates only against high-antigen tumor cells coated with tumor-specific antibodies, sparing healthy tissue and overcoming limitations like T-cell exhaustion and toxicity seen in CAR-T therapies.[1][2][3] The company serves oncology patients and healthcare providers, addressing the challenge of effective, safe treatments for solid tumors, which have resisted traditional cell therapies.[1][5] Backed by NFX and operating at seed stage with 1-10 employees, Gilboa shows early momentum through preclinical data presented at the 2024 AACR meeting, demonstrating tumor eradication and immune memory in animal models.[1][2]
Founded in 2020 as a spinoff from Dr. Yaron Carmi's lab at Tel Aviv University, Gilboa Therapeutics emerged from research into advanced T cell engineering for solid tumors.[1][3] The SolidT technology originated in this academic setting, where scientists addressed CAR-T's shortcomings by creating T cells with an engineered antibody receptor for precise tumor targeting.[2][3] Key early milestones include preclinical validation in challenging animal models and a 2024 AACR presentation highlighting the platform's ability to destroy tumors while establishing immune memory against recurrence.[1] Leadership includes CEO Barry Labinger, with operations co-located in Rehovot, Israel, and Boston, USA, reflecting a blend of Israeli biotech innovation and U.S. market access.[1][3]
Gilboa rides the cell therapy revolution, particularly the push beyond CAR-T limitations for solid tumors, which represent 90% of cancers but lag in immunotherapy success.[1][5] Timing aligns with surging investment in next-gen immunotherapies amid clinical setbacks for first-wave CAR-T in solids, amplified by advances in antibody engineering and gene editing.[2][3] Favorable market forces include a $50B+ oncology cell therapy pipeline, regulatory tailwinds for safer platforms, and Israel's biotech hub status fueling global spinoffs.[1] Gilboa influences the ecosystem by validating academic-to-commercial translation, potentially accelerating antibody-T cell combos and drawing more VC to precision oncology.[1][2]
Gilboa is poised for seed-to-Series A progression, with milestones like IND filings for SolidT in solid tumors likely in 2026-2027, leveraging AACR data for partnerships with big pharma seeking CAR-T alternatives.[1][2] Trends like bispecific antibodies and allogeneic cells will amplify SolidT's modularity, while AI-driven antigen discovery could expand its pipeline.[3] Its influence may grow by pioneering safer, scalable therapies, reshaping solid tumor standards and boosting Israel's role in global immuno-oncology—positioning it as a high-impact player in saving lives through patient immune systems.[1][2]
